MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./270/0.1/20.12.24 Stock

Warrant

DE000ME9GR30

Real-time Bid/Ask 03:52:58 2024-06-07 EDT
0.45 EUR / 0.54 EUR -1.00% Intraday chart for MORGAN STANLEY PLC/CALL/BECTON DICKINSON AND CO./270/0.1/20.12.24
Current month+78.57%
1 month-10.71%
Date Price Change
24-06-06 0.5 +19.05%
24-06-05 0.42 -2.33%
24-06-04 0.43 +2.38%
24-06-03 0.42 +50.00%
24-05-31 0.28 +21.74%

Delayed Quote Börse Stuttgart

Last update June 06, 2024 at 02:57 pm

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer Morgan Stanley
WKN ME9GR3
ISINDE000ME9GR30
Date issued 2024-03-01
Strike 270 $
Maturity 2024-12-20 (197 Days)
Parity 10 : 1
Emission price 0.87
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.12
Lowest since issue 0.19
Spread 0.09
Spread %16.67%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
240.2 USD
Average target price
278.7 USD
Spread / Average Target
+16.04%
Consensus